Last reviewed · How we verify
Sucrose (3%)
Sucrose 3% acts as an osmotic agent and sweetening excipient that may provide mild osmotic laxative effects and serve as a vehicle or stabilizer in pharmaceutical formulations.
At a glance
| Generic name | Sucrose (3%) |
|---|---|
| Sponsor | Hammond, H. Kirk, M.D. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Sucrose is a disaccharide that, at 3% concentration, is primarily used as an inactive ingredient in pharmaceutical preparations rather than as an active therapeutic agent. When ingested orally, high concentrations of sucrose can exert osmotic effects in the gastrointestinal tract, drawing water into the lumen and potentially promoting bowel movements. At 3% concentration, this effect is minimal, and sucrose is more commonly employed as a sweetening agent, stabilizer, or excipient to improve palatability and formulation stability.
Approved indications
Common side effects
- Gastrointestinal distress (at high concentrations)
- Osmotic diarrhea (at high concentrations)
Key clinical trials
- Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study) (PHASE2)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region. (PHASE2)
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
- Sugars in Cigarettes (NA)
- Evaluation of Pine Bark Extract for Anti-fatigue Ergogenic Properties (NA)
- The Effects of Exogenous Ketosis on Ultra-endurance Recovery and Performance (NA)
- ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sucrose (3%) CI brief — competitive landscape report
- Sucrose (3%) updates RSS · CI watch RSS
- Hammond, H. Kirk, M.D. portfolio CI